256 related articles for article (PubMed ID: 6495261)
1. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
Lijnen HR; De Wreede K; Demarsin E; Collen D
Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
[TBL] [Abstract][Full Text] [Related]
2. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.
Zamarron C; Lijnen HR; Van Hoef B; Collen D
Thromb Haemost; 1984 Aug; 52(1):19-23. PubMed ID: 6495259
[TBL] [Abstract][Full Text] [Related]
3. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
5. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
6. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys.
Collen D; De Cock F; Lijnen HR
Thromb Haemost; 1984 Aug; 52(1):24-6. PubMed ID: 6495260
[TBL] [Abstract][Full Text] [Related]
7. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
8. In vitro fibrinolytic activity of recombinant tissue-type plasminogen activator in the plasma of various primate species.
Lijnen HR; Marafino BJ; Collen D
Thromb Haemost; 1984 Dec; 52(3):308-10. PubMed ID: 6543405
[TBL] [Abstract][Full Text] [Related]
9. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
[TBL] [Abstract][Full Text] [Related]
10. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.
Korninger C; Collen D
Thromb Haemost; 1981 Aug; 46(2):561-5. PubMed ID: 6795744
[TBL] [Abstract][Full Text] [Related]
11. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
Lourenço DM; Dosne AM; Kher A; Samama M
Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
[TBL] [Abstract][Full Text] [Related]
12. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
Collen D; Stassen JM; Marafino BJ; Builder S; De Cock F; Ogez J; Tajiri D; Pennica D; Bennett WF; Salwa J
J Pharmacol Exp Ther; 1984 Oct; 231(1):146-52. PubMed ID: 6541693
[TBL] [Abstract][Full Text] [Related]
13. Role of alpha 2-antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma.
Declerck PJ; Lijnen HR; Verstreken M; Collen D
Thromb Haemost; 1991 Apr; 65(4):394-8. PubMed ID: 2057921
[TBL] [Abstract][Full Text] [Related]
14. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.
Gurewich V; Pannell R; Louie S; Kelley P; Suddith RL; Greenlee R
J Clin Invest; 1984 Jun; 73(6):1731-9. PubMed ID: 6725557
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
Gurewich V; Pannell R; Broeze RJ; Mao J
J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
Gurewich V; Pannell R
Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
[TBL] [Abstract][Full Text] [Related]
17. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
Kawakami K; Takahashi A; Yoshimoto T
No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
[TBL] [Abstract][Full Text] [Related]
18. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
Samama M; Nguyen G; Desnoyers P; Lourenco DM; Fretault J; Horellou MH; Conard J; Szwarcer E; Verdy E; Vahanian A
Fundam Clin Pharmacol; 1988; 2(6):509-23. PubMed ID: 3149257
[TBL] [Abstract][Full Text] [Related]
19. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.
Hanbücken FW; Schneider J; Günzler WA; Friderichs E; Giertz H; Flohé L
Arzneimittelforschung; 1987 Aug; 37(8):993-7. PubMed ID: 3118890
[TBL] [Abstract][Full Text] [Related]
20. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
